Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
Reaffirms full year 2018 forecast and 2020 goals Revises 1Q 2018 forecast GAITHERSBURG, Md. , Feb. 22, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) reported financial results...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
GAITHERSBURG, Md. , Feb. 08, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 22, 2018 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
GAITHERSBURG, Md. , Jan. 04, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety,...
Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
GAITHERSBURG, Md. , Jan. 04, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety,...
Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
GAITHERSBURG, Md. , Jan. 03, 2018 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the...
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations GAITHERSBURG, Md. , Dec. 12, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that...
Emergent BioSolutions to Host 2017 Analyst & Investor Day
GAITHERSBURG, Md. , Nov. 30, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York...
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
GAITHERSBURG, Md. , Nov. 20, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental...
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
GAITHERSBURG, Md. , Nov. 14, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has issued a Notice of Termination of Conversion Rights for all of its...
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
GAITHERSBURG, Md. , Nov. 02, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017 . FINANCIAL...
Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
GAITHERSBURG, Md. , Oct. 19, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS) will release its financial results for the third quarter and nine months of 2017 immediately after market...
Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi
GAITHERSBURG, Md. , Oct. 06, 2017 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Sanofi’s ACAM2000 ® , (Smallpox (Vaccinia)...